---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-017980"
form_type: "8-K"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T13:43:38.029688+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Collegium Q3 revenue $136.7M (+8% YoY), adj. EBITDA record $89.4M, guidance tightened

## Summary
- GAAP net income $20.6M vs $0.5M; diluted EPS $0.53; adjusted EPS $1.34.
- Belbuca net revenue $45.4M (+17% YoY); Xtampza ER $39.8M; Nucynta franchise $47.5M.
- Updated FY23 guidance: revenue $565-570M, adj. EBITDA $360-365M, op. expenses $125-130M.
- Nucynta exclusivity extended to July 2026; board authorized $25M ASR program.
- Cash and securities $304.6M, up from $173.7M at Dec 31, 2022.

## SEC filing metadata
- accession: 0001558370-23-017980
- form_type: 8-K
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000155837023017980/0001558370-23-017980-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000155837023017980/coll-20231107x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-017980
- JSON: https://secwatch.observer/filing/0001558370-23-017980.json
- Plain text: https://secwatch.observer/filing/0001558370-23-017980.txt

## Key facts
- Earnings Releases
  COLLEGIUM PHARMACEUTICAL, INC reported the quarter ended September 30, 2023 results: revenue $136.7 million, net income $20.6 million, EPS $0.61 GAAP earnings per share (basic) and $0.53 GAAP earnings per share (diluted). Guidance reaffirmed.
  - Period: the quarter ended September 30, 2023
  - Revenue: $136.7 million
  - Net income: $20.6 million
  - EPS: $0.61 GAAP earnings per share (basic) and $0.53 GAAP earnings per share (diluted)
  - Guidance: reaffirmed
  - Result: reported results
  source text: not filed, under Item 2.02 of this Current Report on Form 8-K. ​ --- EX-99.1 (EX-99.1) --- ​ Collegium Reports Third Quarter 2023 Financial Results ​ – Q3’23 Net Revenue of $136.7 Million, Up 8% Year-over-Year – ​ – Q3’23 GAAP Net Income of $20.6 Million vs. Q3’22 GAAP Net Income of $0.5 Million – ​ – Record Q3’23 Adjusted EBITDA of $89.4 Million, Up 19%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267565/000155837023017980/0001558370-23-017980-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.